Search

Displaying results 9861 - 9870 of 10000 in total
  1. Drug

    Nezastomig

    go.drugbank.com/drugs/DB19061
    Investigational

    Nezastomig is under investigation in clinical trial NCT06085664 (A Pilot Presurgical Trial of REGN5678 (Anti-psma X CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

  2. Drug

    Amdoxovir

    go.drugbank.com/drugs/DB06619
    Investigational

  3. Drug

    Enrasentan

    go.drugbank.com/drugs/DB06460
    Experimental

  4. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  5. Drug

    P54

    go.drugbank.com/drugs/DB05451
    Experimental

    P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis. It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory gen...

  6. Drug

    Capravirine

    go.drugbank.com/drugs/DB08502
    Investigational

  7. Drug

    Olinvacimab

    go.drugbank.com/drugs/DB16265
    Investigational

    Olinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).

  8. Drug

    Olodanrigan

    go.drugbank.com/drugs/DB16266
    Investigational

    Olodanrigan is under investigation in clinical trial NCT03297294 (Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)).

  9. Drug

    Romilkimab

    go.drugbank.com/drugs/DB16318
    Investigational

    Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis).

  10. Drug

    Torudokimab

    go.drugbank.com/drugs/DB16671
    Investigational

    Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).